iSpecimen Stock Set to Reverse Split on Tuesday, April 28th (NASDAQ:ISPC)

iSpecimen Inc. (NASDAQ:ISPC) shares are scheduled to reverse split before the market opens on Tuesday, April 28th. The 1-40 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 27th.

iSpecimen Stock Performance

Shares of iSpecimen stock traded down $0.03 on Friday, reaching $0.13. The company had a trading volume of 27,448,865 shares, compared to its average volume of 22,726,467. The firm’s 50 day moving average price is $0.20 and its two-hundred day moving average price is $0.40. The firm has a market cap of $3.87 million, a PE ratio of -0.06 and a beta of 1.98. iSpecimen has a 52-week low of $0.10 and a 52-week high of $3.18.

iSpecimen (NASDAQ:ISPC) last released its quarterly earnings results on Wednesday, April 1st. The company reported ($0.74) earnings per share (EPS) for the quarter. The company had revenue of $0.05 million during the quarter. iSpecimen had a negative net margin of 543.37% and a negative return on equity of 496.31%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a research note on Tuesday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC acquired a new stake in iSpecimen Inc. (NASDAQ:ISPC) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned approximately 0.30% of iSpecimen as of its most recent filing with the Securities & Exchange Commission. 13.62% of the stock is currently owned by institutional investors and hedge funds.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.